GlassScriptPhysician profile
Kimberly D Johnson
NPI 1396717104
$1,035.39
in general payments reported to CMS, 2019-2025
16 companies · $319 in 2025
The $319 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $18.73 · 2021: $262 · 2022: $105 · 2023: $58.12 · 2024: $159 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $536.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $269.20 | 2021-2025 | Vraylar |
| Lilly USA, LLC | $130.30 | 2019-2025 | Zepbound, Mounjaro |
| Gilead Sciences, INC. | $100.04 | 2019-2023 | |
| Pfizer INC. | $98.35 | 2019-2025 | |
| Indivior INC. | $93.56 | 2021-2025 | Sublocade |
| Braeburn INC. | $75.18 | 2024-2025 | Brixadi |
| Dexcom, INC. | $60.71 | 2025 | Dexcom G6 Transmitter |
| Alkermes, INC. | $46.16 | 2024-2025 | Vivitrol |
| Otsuka America Pharmaceutical, INC. | $31.88 | 2024-2025 | Rexulti, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $24.29 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.22 | 2025 | Caplyta |
| Abbott Laboratories | $22.27 | 2024 | Freestyle Libre |
| Novo Nordisk INC | $18.73 | 2020 | |
| Janssen Pharmaceuticals, INC | $16.58 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.47 | 2025 | Xifaxan |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $9.45 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.